Thus, the available evidence suggests that GPER-mediated EMT is a prevalent clinical phenomenon in tumorigenic cells, highlighting its role in the potential hallmarks of BC and feasible therapeutic options to overcome endocrine resistance. Here, GPER1 is linked to breast cancer.